Orano Med Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Orano Med Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.
Executive BD thesis
Orano Med is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 24 records at the decision date. The lead returned asset is 212Pb-AR-RMX, associated with SSTR and Somatostatin Receptor-Positive Neuroendocrine Tumor, at Phase 2. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.
A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | 212Pb-AR-RMX | Orano Med LLC | Phase 2 | Pipeline record: SSTR; Somatostatin Receptor-Positive Neuroendocrine Tumor. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sanofi Inks $326M Radiopharma Deal With Orano | Phase 2 asset with SSTR exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 2 | MP-0712 | Orano Med Manufacturing SAS | Phase 1 | Pipeline record: DLL3; Neuroendocrine Tumors, Small Cell Lung Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | Phase 1 asset with DLL3 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 3 | 212Pb-PRIT | Orano Med Manufacturing SAS | Phase 1 | Pipeline record: target not returned; Colorectal Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sanofi Inks $326M Radiopharma Deal With Orano | Phase 1 asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 4 | 212Pb-PSMA | Orano Med Manufacturing SAS | IND Application | Pipeline record: PSMA; Prostatic Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | IND Application asset with PSMA exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 5 | [203Pb]Pb-DOTATATE | Orano Med Manufacturing SAS | Preclinical | Pipeline record: target not returned; Neuroendocrine Tumors. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sanofi Inks $326M Radiopharma Deal With Orano | Preclinical asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
Shortlist interpretation. Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2024-10-17 | Sanofi Inks $326M Radiopharma Deal With Orano | Active | Not disclosed |
| 2024-09-12 | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | Active | Not disclosed |
Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.
Financial capacity and partnering pressure
- OncoTherapy Science, Inc. - Annual securities report-18th Period(2018.04.01-2019.03.31): OncoTherapy Science, Inc. - Annual securities report-18th Period(2018.04.01-2019.03.31) ② 竞合について 当连结会计年度における现金及び现金同等物（以下「资金」という。）は、4,857百万円（前连结会计年度比 1,882百万円减少）となりました。 当连结会计年度のキャッシュ・フローの概况は以下のとおりです。 （営业活动によるキャッシュ・フロー） 当连结会计年度における営业活动によるキャッシュ・フローは、2,373百万円の资金の减少（前连结会计年度 末は3,035百万円の减少）となりました。これは、减価偿却费391百万円、减损损失318百万円の计上、および未 払法人税等102百万円の増加により资金が増加した一方、税金等调整前当期纯损失3,194百万円を计上したことが 主な要因となっております。 （投资活动によるキャッシュ・フロー） 当连结会计年度における投资活动によるキャッシュ・フローは、74百万円の资金の减少（前连结会计年度末は 446百万円の减少）となりました。これは、主として有形固定资产の取得による支出71百万円によるものです。 （财务活动によるキャッシュ・フロー） 当连结会计年度における财务活动によるキャッシュ・フローは、565百万円の资金の増加（前连结会计年度末 は150百万円の増加）となりました。これは、主として株式の発行による収入553百万円によるものです。 ③生产、受注及び贩売の実绩 a.生产実绩 当社の业务は、业务の性格上、生产として把握することが困难であるため、记载を省略しております。 b.受注実绩 当连结会计年度における受注実绩については、贩売高に比べて受注高の重要性が乏しいことから、记载を省略 しております。 c.贩売実绩
- ORAMED PHARMACEUTICALS INC. - 2024 Quarterly report: ORAMED PHARMACEUTICALS INC. - 2024 Quarterly report Research and Development Expenses During the three month period ended March 31, 2024, cash and cash equivalents increased to $18,576,000, from $9,055,000 as of December 31, 2023. The increase was mainly due to the reasons described below. Operating activities used cash of $1,476,000 in the three month period ended March 31, 2024, compared to $5,549,000 used in the three month period ended March 31, 2023. Cash used in operating activities primarily consisted of research and development, sales and marketing and general and administrative expenses and changes in stock-based compensation expenses, interest on deposits, interest paid on the Short- Term Borrowings, accounts payable and accrued expenses. Investing activities provided cash of $29,998,000 in the three month period ended March 31, 2024, compared to cash used in investing activiti
- OncoTherapy Science, Inc. - Annual securities report-15th Period(2015.04.01-2016.03.31): OncoTherapy Science, Inc. - Annual securities report-15th Period(2015.04.01-2016.03.31) １【业绩等の概要】 これらの结果、当连结会计年度における连结事业収益につきましては、提携先制薬企业からのマイルストー ン、开発协力金および研究协力金の受领、ならびにTCR解析受托売上などにより、266百万円（前期比503百万円の 减少）となりました。 また、医薬品候补物质等の基础研究、创薬研究の継続的な実施による研究开発费用の计上に加え、低分子医 薬、がん特异的ペプチドワクチン、抗体医薬の３つの领域についての临床开発进展による费用计上、ならびにが ん个别化医疗への取组みに必须の技术であるTCR解析サービスの研究开発费用の计上を主な要因として、连结営业 损失は2,980百万円（前期は1,962百万円の损失）、连结経常损失は2,963百万円（前期は1,939百万円の损失）、 亲会社株主に帰属する当期纯损失は2,788百万円（前期は1,334百万円の损失）となりました。 なお、当社および连结子会社は「医薬品の研究および开発」ならびにこれらに関连する事业内容となってお り、事业区分が単一セグメントのため、セグメント别の记载を省略しております。 (2) キャッシュ・フローの状况 当连结会计年度における现金及び现金同等物（以下「资金」という。）は、13,070百万円（前连结会计年度末比 7,998百万円増加）となりました。 当连结会计年度のキャッシュ・フローの概况は以下の通りです。 （営业活动によるキャッシュ・フロー）
Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.
Current-awareness events and outreach triggers
The Current Awareness news_search call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.
The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.
IP and freedom-to-operate risk screen
The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.
Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.
Recommended deal structures
- Regional license: useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.
- Co-development: appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.
- Option-to-license: reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.
- Research or platform collaboration: suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.
- Structured financing: may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.
Outreach rationale and first-contact plan
- Identify the decision owner. Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.
- Lead with one verifiable gap. Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.
- Attach a concise evidence package. Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.
- Offer a structure. Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.
- Define the diligence sequence. Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.
Decision memo
ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH. Orano Med offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.
Required next diligence: refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 22 July 2026. Counts, ownership and statuses may change as records update.
